Cocrystal Pharma, Inc. - Product Pipeline Review - 2016

Published: Jun, 2016 | Pages: 44 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Cocrystal Pharma, Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Cocrystal Pharma, Inc. - Product Pipeline Review - 2016', provides an overview of the Cocrystal Pharma, Inc.'s pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Cocrystal Pharma, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Cocrystal Pharma, Inc.
- The report provides overview of Cocrystal Pharma, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Cocrystal Pharma, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Cocrystal Pharma, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Cocrystal Pharma, Inc.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Cocrystal Pharma, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cocrystal Pharma, Inc.'s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Cocrystal Pharma, Inc. Snapshot 6
Cocrystal Pharma, Inc. Overview 6
Key Information 6
Key Facts 6
Cocrystal Pharma, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Cocrystal Pharma, Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Out-Licensed Products 12
Out-Licensed Products/Combination Treatment Modalities 13
Cocrystal Pharma, Inc. - Pipeline Products Glance 14
Cocrystal Pharma, Inc. - Clinical Stage Pipeline Products 14
Phase I Products/Combination Treatment Modalities 14
Cocrystal Pharma, Inc. - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Cocrystal Pharma, Inc. - Drug Profiles 17
CC-31244 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
CC-1845 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
CC-2068 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
CC-2069 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
CDI-244 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Gene Therapy for Hepatitis B and Human Papilloma Virus Infections 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
CC-31326 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
RS-1137 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
RS-1142 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
RS-1145 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
RS-930 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
RS-961 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecule for Hepatitis C 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecules to Inhibit PB2 for Influenza 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Small Molecules to Inhibit RNA Dependent RNA Polymerase for Common Cold 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Small Molecules to Inhibit RNA Dependent RNA Polymerase for Dengue Virus Infections 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecules to Inhibit RNA Dependent RNA Polymerase for Norovirus Infections 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Cocrystal Pharma, Inc. - Pipeline Analysis 34
Cocrystal Pharma, Inc. - Pipeline Products by Target 34
Cocrystal Pharma, Inc. - Pipeline Products by Route of Administration 35
Cocrystal Pharma, Inc. - Pipeline Products by Molecule Type 36
Cocrystal Pharma, Inc. - Pipeline Products by Mechanism of Action 37
Cocrystal Pharma, Inc. - Recent Pipeline Updates 38
Cocrystal Pharma, Inc. - Dormant Projects 41
Cocrystal Pharma, Inc. - Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 43
Disclaimer 44

List of Tables

Cocrystal Pharma, Inc., Key Information 6
Cocrystal Pharma, Inc., Key Facts 6
Cocrystal Pharma, Inc. - Pipeline by Indication, 2016 8
Cocrystal Pharma, Inc. - Pipeline by Stage of Development, 2016 10
Cocrystal Pharma, Inc. - Monotherapy Products in Pipeline, 2016 11
Cocrystal Pharma, Inc. - Out-Licensed Products in Pipeline, 2016 12
Cocrystal Pharma, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 13
Cocrystal Pharma, Inc. - Phase I, 2016 14
Cocrystal Pharma, Inc. - Preclinical, 2016 15
Cocrystal Pharma, Inc. - Discovery, 2016 16
Cocrystal Pharma, Inc. - Pipeline by Target, 2016 34
Cocrystal Pharma, Inc. - Pipeline by Route of Administration, 2016 35
Cocrystal Pharma, Inc. - Pipeline by Molecule Type, 2016 36
Cocrystal Pharma, Inc. - Pipeline Products by Mechanism of Action, 2016 37
Cocrystal Pharma, Inc. - Recent Pipeline Updates, 2016 38
Cocrystal Pharma, Inc. - Dormant Developmental Projects,2016 41
Cocrystal Pharma, Inc., Other Locations 42